In addition, series B investors include 6 Dimensions Capital, Longwood Fund, Bessemer Venture Partners, GV, and Novartis Venture Fund.
TScan designs therapies that reprogram a patient's own T cells to recognize and fight their cancer using naturally-occurring TCRs that find and destroy shared cancer targets.
The TScan technology process allows TCRs to be scanned against target antigens in a genome-wide, high-throughput, and unbiased fashion.
TScan is developing a portfolio of TCR therapies for patients suffering from both liquid and solid tumors, and has already discovered, through this process, novel antigens from TCRs, novel TCRs from known antigens, and previously uncharacterised off-targets of known TCRs.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients